"While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk," said Dr Tedros ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

: WHO-approved HIV preventive drug Lenacapavir to be rolled out next year to allow for changes in existing guidelines and ...

Kenya is among nine African countries selected to introduce Lenacapavir, a groundbreaking long-acting injectable HIV ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

The World Health Organization has approved the rollout of an injectable HIV preventive drug; Lenacapavir or LEN. The National ...

We’ve come a long way in treating HIV, the virus that can lead to AIDs. Just last month, the FDA approved a medication that ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...